All News

Experts dismantled the assumption that direct-to-patient is a universal affordability solution, offering manufacturers a practical framework for deciding which model is actually right.

Philadelphia oncology leaders tackle gaps in biomarker testing, breast cancer advances, myeloma innovation, and clinical trial equity.

New data show how systemic inflammation independently raises the risk of CKD progression and cardiovascular events after acute myocardial infarction.

This week, a Capitol hearing spotlights Medicare fraud gaps, reports warn of equity setbacks, community oncology boosts survival, and Medicaid work rules loom.

AI drives community oncology transformation as practice leaders offer examples of what is working in community oncology to streamline calls, triage, and documentation.

Rani Bansal, MD, discusses breast cancer subtypes, racial disparities in triple-negative disease, self-advocacy for young patients, and diversity in clinical trials.

The therapy receives FDA approval for Alzheimer disease agitation, backed by phase 3 data showing significant symptom reduction and delayed relapse vs placebo.

Experts at AXS26 laid out why advanced therapies are underutilized and what payers, providers, and manufacturers must do together to change that.

At NAACOS 2026, experts highlighted how real-world AI tools are improving care delivery, outcomes, and efficiency across the health care landscape.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

The results show that semaglutide could be a novel treatment for patients with alcohol use disorder moving forward.

The new work requirements for Medicaid eligibility, included in the One Big Beautiful Bill Act, will officially be required in January 2027.

Education on colorectal cancer symptoms and screening can help to prevent advancing disease in a cancer that is seeing increased incidence in younger adults.

A new Commonwealth Fund report finds persistent racial health disparities nationwide despite coverage gains, with major gaps in care, access, and outcomes.

Experts discussed value-based oncology care, CAR T-cell therapy access gaps, myeloma advances, and bispecific therapy challenges.

Experts examined oncology care innovation, access gaps to CAR T-cell therapy, advances in myeloma care, and partnerships in value-based care.

FIT-DNA modestly improved CRC screening in CHCs, but uptake and follow-up colonoscopy rates remained low.

Specialty pharmacies play a critical role in connecting patients with assistance programs to combat growing financial complexities.

Karen Fancher, PharmD, BCOP, emphasizes a pharmacist’s pivotal role in CLL care through communication, adherence strategies, and bridging patients with medical teams.

Patients with advanced glaucoma had better outcomes when treated with trabeculectomy rather than using medication first.

At AXS26, leaders shared the hard-won organizational, strategic, and operational lessons from rounds 1, 2, and 3 of the Medicare Drug Price Negotiation Program.

Experts examine what is working in production, where the guardrails are being tested, and why the most transformative chapter of AI in health care hasn’t started yet.

New research incorporating Flatiron Health and SEER data, confirms community oncology care matches or beats other settings, says Diana Verrilli, MS, Navista.

Bringing these curative treatments to more patients means making them available at the community practice level. But that's a big lift, according to experts who spoke at a COA session.

Wastewater SARS-CoV-2 levels correlated with hospital COVID-19 cases, supporting targeted screening of asymptomatic patients.

The BCBSNC Foundation's focus on access to care, health through food, and youth mental health aligns with broader national health trends.

Based on their findings, the 2 experts suggested that tiered benefit design may already strongly influence consumer choices.

Newly FDA-approved doravirine/Islatravir maintained HIV suppression in phase 3 trials with comparable safety and minimal metabolic effects.